These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9882029)

  • 1. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam.
    Settle CD; Wilcox MH; Fawley WN; Corrado OJ; Hawkey PM
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1217-23. PubMed ID: 9882029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea.
    Wilcox MH; Freeman J; Fawley W; MacKinlay S; Brown A; Donaldson K; Corrado O
    J Antimicrob Chemother; 2004 Jul; 54(1):168-72. PubMed ID: 15163654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal concentrations of piperacillin and tazobactam in elderly patients.
    Wilcox MH; Brown A; Freeman J
    J Antimicrob Chemother; 2001 Jul; 48(1):155-6. PubMed ID: 11418534
    [No Abstract]   [Full Text] [Related]  

  • 4. Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin.
    Alston WK; Ahern JW
    J Antimicrob Chemother; 2004 Mar; 53(3):549-50. PubMed ID: 14963072
    [No Abstract]   [Full Text] [Related]  

  • 5. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?
    Kundrapu S; Sunkesula VC; Jury LA; Cadnum JL; Nerandzic MM; Musuuza JS; Sethi AK; Donskey CJ
    BMC Infect Dis; 2016 Apr; 16():159. PubMed ID: 27091232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization.
    Lin HJ; Hung YP; Liu HC; Lee JC; Lee CI; Wu YH; Tsai PJ; Ko WC
    J Microbiol Immunol Infect; 2015 Apr; 48(2):183-9. PubMed ID: 24064285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic prescribing policy and Clostridium difficile diarrhoea.
    O'Connor KA; Kingston M; O'Donovan M; Cryan B; Twomey C; O'Mahony D
    QJM; 2004 Jul; 97(7):423-9. PubMed ID: 15208430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections.
    Mendez MN; Gibbs L; Jacobs RA; McCulloch CE; Winston L; Guglielmo BJ
    Pharmacotherapy; 2006 Jan; 26(1):61-7. PubMed ID: 16509027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of diarrhoea, Clostridium difficile and cefotaxime in the elderly.
    Starr JM; Impallomeni M
    Biomed Pharmacother; 1997; 51(2):63-7. PubMed ID: 9161469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: a review.
    Sanders CV
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S21-6. PubMed ID: 7962985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime.
    Impallomeni M; Galletly NP; Wort SJ; Starr JM; Rogers TR
    BMJ; 1995 Nov; 311(7016):1345-6. PubMed ID: 7496287
    [No Abstract]   [Full Text] [Related]  

  • 12. Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile.
    Stiefel U; Nerandzic MM; Koski P; Donskey CJ
    J Antimicrob Chemother; 2008 Nov; 62(5):1105-8. PubMed ID: 18693236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Clostridium difficile associated diarrhoea in a tertiary care hospital.
    Kaneria MV; Paul S
    J Assoc Physicians India; 2012 Nov; 60():26-8. PubMed ID: 23767199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital-acquired Clostridium difficile diarrhoea and herd immunity.
    Starr JM; Rogers TR; Impallomeni M
    Lancet; 1997 Feb; 349(9049):426-8. PubMed ID: 9033485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
    Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2005 Jun; 55(6):974-82. PubMed ID: 15860551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. Cefotaxime compares favourably with other third generation cephalosporins.
    Rothschild E; Rauss A; Danan G
    BMJ; 1996 Mar; 312(7033):778. PubMed ID: 8605486
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy.
    McNulty C; Logan M; Donald IP; Ennis D; Taylor D; Baldwin RN; Bannerjee M; Cartwright KA
    J Antimicrob Chemother; 1997 Nov; 40(5):707-11. PubMed ID: 9421320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.
    Charbonneau P
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S43-8. PubMed ID: 7962989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. Mortality due to C difficile colitis in elderly people has been underestimated.
    Lesna M; Parham DM
    BMJ; 1996 Mar; 312(7033):778. PubMed ID: 8605487
    [No Abstract]   [Full Text] [Related]  

  • 20. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis.
    Wilcox MH
    Best Pract Res Clin Gastroenterol; 2003 Jun; 17(3):475-93. PubMed ID: 12763508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.